This firm currently holds 70.65
M in liabilities with Debt to Equity (D/E) ratio of 0.72, which is about average as compared to similar companies.
What is the right price you would pay to acquire a share of Oncorus? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
Watch out for price decline
Please consider monitoring Oncorus on a daily basis if you are holding a position in it. Oncorus is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Oncorus stock to be traded above the $1 level to remain listed. If Oncorus stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
What is happening with Oncorus this year
Annual and quarterly reports issued by Oncorus are formal
financial statements that are published yearly and quarterly and sent to Oncorus stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Oncorus often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Is OncorusInc a risky opportunity?
Let's check the volatility. OncorusInc is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind OncorusInc (USA Stocks:ONCR) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. buying a share of an OncorusInc stock makes you a part-owner of that company.
OncorusInc Current Consensus
Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering OncorusInc. The OncorusInc consensus assessment is calculated by taking the average estimates from all of the analysts covering OncorusInc
| Strong Buy | 1 | 33.33 |
| Buy | 0 | 0.0 |
| Hold | 2 | 66.67 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Our Conclusion on OncorusInc
While some other companies under the biotechnology industry are still a bit expensive, OncorusInc may offer a potential longer-term growth to retail investors. The bottom line, as of the 14th of May 2023, our analysis shows that OncorusInc follows the market closely. The enterprise is
overvalued and projects
very high probability of financial unrest for the next 2 years. Our ongoing 90 days recommendation on the enterprise is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Aina Ster is a Member of Macroaxis Editorial Board. Aina delivers weekly perspective on ongoing market and economic trends, analysis and tips from predictive analysis to forecasting across various financial instruments.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Oncorus. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
